Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2

Mojsak, Damian; Kuklińska, Beata; Dębczyński, Michał; Mróz, Robert

doi:10.5114/wo.2021.105031

Cited by 3 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Late or incorrect diagnosis is aggravated by a lack of access to appropriate therapies and expertise. Recent years have brought new treatment options for patients with non-small-cell LC, such as immunotherapy in stage IV and stage III, but reimbursement is comparatively limited [ 45 , 51 ].…”

Section: Resultsmentioning

confidence: 99%

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

et al. 2022

View full text Add to dashboard Cite

Cancer is the second leading cause of mortality in EU countries, and the needs to tackle cancer are obvious. New scientific understanding, techniques and methodologies are opening up horizons for significant improvements in diagnosis and care. However, take-up is uneven, research needs and potential outstrip currently available resources, manifestly beneficial practices—such as population-level screening for lung cancer—are still not generalised, and the quality of life of patients and survivors is only beginning to be given attention it merits. This paper, mainly based on a series of multistakeholder expert workshops organised by the European Alliance for Personalised Medicine (EAPM), looks at some of those specifics in the interest of planning a way forward. Part of this exercise also involves taking account of the specific nature of Europe and its constituent countries, where the complexities of planning a way forward are redoubled by the wide variations in national and regional approaches to cancer, local epidemiology and the wide disparities in health systems. Despite all the differences between cancers and national and regional resources and approaches to cancer care, there is a common objective in pursuing broader and more equal access to the best available care for all European citizens.

show abstract

Section: Resultsmentioning

confidence: 99%

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Patients with NSCLC with poor ECOG PS treated with immune checkpoint inhibitors had significantly worse survival outcomes and were significantly more likely to use healthcare resources ( 34 ). Possible reasons for this are as follows: (1) higher immune function—patients with a lower ECOG score may have a stronger immune system, which could enhance the effectiveness of immunotherapy ( 33 ); (2) lower tumor burden—patients with a lower ECOG score may have a reduced tumor burden, which could make them more responsive to immunotherapy ( 36 ); and (3) better treatment adherence—patients with a lower ECOG score are more likely to adhere to treatment regimens, which could improve treatment outcomes ( 37 ). It is important to note that the relationship between ECOG score and immunotherapy outcomes is complex and further research is needed.…”

Section: Discussionmentioning

confidence: 99%

Effect of autologous dendritic cell cytokine-induced killer on refractory metastatic colorectal cancer: a matched case–control comparative study

Chang,

Ke,

Chen

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

BackgroundPatients with metastatic colorectal cancer (mCRC) who are refractory to two or more lines of systemic chemotherapy have limited therapeutic options. The aim of this study was to evaluate the effect of autologous dendritic cell cytokine-induced killer (DC-CIK) transfer on the survival of patients with mCRC who are refractory or intolerant to at least two lines of systemic chemotherapies.MethodsA matched case–control comparative study was conducted with patients who received DC-CIK immunotherapy in addition to standard chemotherapy (cases) and those with standard chemotherapy alone (controls). The primary objective was to compare the duration of oncologic survival, including overall survival (OS) and progression-free survival (PFS), between the two groups.ResultsA total of 27 cases and 27 controls were included. The median OS in the DC-CIK case group was 18.73 ± 5.48 months, which was significantly longer than that in the control group (14.23 ± 1.90 months, p = 0.045). However, there was no significant difference in PFS between the two groups (p = 0.086). Subgroup analysis showed that in patients with liver or extra-regional lymph node metastasis, DC-CIK cases had longer OS than controls (17.0 vs. 11.87 months, p = 0.019; not match vs. 6.93 months, p = 0.002, respectively). In patients with Eastern Cooperative Oncology Group (ECOG) scale 0 or wild RAS/BRAF, DC-CIK cases showed a significant increase in OS duration compared to controls (28.03 vs. 14.53 months, p = 0.038; 18.73 vs. 11.87 months, p = 0.013, respectively).ConclusionsThe addition of autologous DC-CIK to standard chemotherapy had a positive effect on OS of patients with refractory mCRC, especially those with liver or extra-regional lymph node metastasis, ECOG = 0, and wild RAS/BRAF status.

show abstract

“…There is an increase of PFS in Adenocarcinoma and negative smoking. Kaplan-Meier analysis for relation of overall survival (OS) (months) with pathology, age and ECOG PS is shown in table (6). Results showed a highly statistically significant association between age (< 60 years), ECOG PS and the OS (p <0.01) as shown in figures ( 4) & ( 5), respectively.…”

Section: B) Dna Amplification and Real-time Pcr Allelic Discriminatio...mentioning

confidence: 92%

“…Results showed a highly statistically significant association between age (< 60 years), ECOG PS and the OS (p <0.01) as shown in figures ( 4) & ( 5), respectively. Moreover, the OS is significantly associated between with adenocarcinoma (p<0.05) as shown in figure (6). Association among the ERCC1 genotyping & the OS could not be assessed as all the dead patients were CC genotyped.…”

Section: B) Dna Amplification and Real-time Pcr Allelic Discriminatio...mentioning

confidence: 99%

See 1 more Smart Citation

Single Nucleotide Polymorphism of ERCC1 Gene in Patients with Non-Small Cell Lung Cancer and its Relation to the Response to Platinum Chemotherapy

Zaghla¹,

Abdelhakam²,

Elmageed³

et al. 2022

The Egyptian Journal of Hospital Medicine

View full text Add to dashboard Cite

Background: Non-small cell lung cancer (NSCLC) accounts for eighty five percent of lung cancer cases. Among drugs most commonly used are platinum-based chemotherapy as cisplatin and carboplatin & 3 rd generation chemotherapy. Excision Repair Cross Complementing Group 1 (ERCC1) Gene is one of members of nucleotide excision repair pathway. It causes inhibition in the action produced by platinum and third generation chemotherapy. So, the produced DNA repair will be resistance to these drugs. Single nucleotide polymorphism in ERCC1 impairs this function and this may help in prediction of response to platinum-based chemotherapy. Aim of the Work: This work aimed to study association among single nucleotide polymorphism of ERCC1 rs11615 in studied cases with non-small cell lung cancer and the response to platinum-based chemotherapy as to reduce exposure of chemotherapy side effect. Materials & Methods: research was done on 50 NSCLC patients. Thirty of them were non-responders to platinum-based chemotherapy & other 20 were responders based on RECIST criteria. Detection of the ERCC1 (T/C) polymorphism by real-time PCR was done for all patients' groups. Results: In responders' group, 19 patients (95%) had wild type homozygous CC genotype & 1patient (5%) had heterozygous TC genotype. In non-responders' group, 29 patients (96.7%) had wild type homozygous CC genotype and one patient (3.3%) had TC genotypes. There was no significant statistical variation observed among responders' & non-responders' groups regarding genotype frequencies (𝑥 2 = 0.8, p>0.05). Conclusion: Our findings did not support existence of significant link among ERCC1 rs 11615 polymorphism & response to platinum-based chemotherapy in advanced cases of NSCLC.

show abstract

Immunotherapy in patients with non-small cell lung cancer with ECOG PS 2

Cited by 3 publications

References 14 publications

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

How Can the EU Beating Cancer Plan Help in Tackling Lung Cancer, Colorectal Cancer, Breast Cancer and Melanoma?

Effect of autologous dendritic cell cytokine-induced killer on refractory metastatic colorectal cancer: a matched case–control comparative study

Single Nucleotide Polymorphism of ERCC1 Gene in Patients with Non-Small Cell Lung Cancer and its Relation to the Response to Platinum Chemotherapy

Contact Info

Product

Resources

About